Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2023-02-14 Major Shareholding Noti…
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
AMENDMENT TO FORM SC 13D
Major Shareholding Notification
2023-02-14 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering, specifically detailing the terms of an offering of common stock and pre-funded warrants. It includes information about the offering price, number of shares, use of proceeds, risk factors, and legal disclaimers. This type of document is a capital markets offering document, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2023-02-14 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 13, 2023, reporting the entry into a material definitive agreement related to a securities purchase agreement for a registered direct offering. It details the issuance of common stock and pre-funded warrants, the expected proceeds, and use of funds. The document includes legal opinions and a press release about the offering. There are no financial statements or comprehensive financial data presented, only an announcement of a financing transaction. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2023-02-14 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-13 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-10 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 25, 2023, by Disc Medicine, Inc. It announces the entry into a material definitive agreement with SVB Securities LLC for an 'at the market' offering of up to $100 million of common stock. The document details the terms of the sales agreement, commission, and legal opinions attached as exhibits. There are no financial statements or quarterly/annual results presented, nor is this a transcript, proxy, or governance report. The primary content is an update on a financing activity (share issuance agreement). Therefore, this fits the category of Capital/Financing Update (CAP). The document length is over 6000 characters and contains substantive details about the financing agreement, not just an announcement of a report publication or a certification. Hence, the classification is CAP with high confidence.
2023-01-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.